Literature DB >> 2355021

A retinoic acid-responsive gene, MK, found in the teratocarcinoma system. Heterogeneity of the transcript and the nature of the translation product.

M Tomomura1, K Kadomatsu, S Matsubara, T Muramatsu.   

Abstract

A newly identified gene, MK, is transiently expressed in the early stages of embryonal carcinoma cell differentiation and in the mid-gestation period of mouse embryogenesis (Kadomatsu, K., Tomomura, M., and Muramatsu, T. (1988) Biochem. Biophys. Res. Commun. 151, 1312-1318). Analysis of various MK cDNA clones revealed differences in the 5'-region. So far three classes of cDNA clones (MK1, MK2, and MK3) have been identified; they were different in the 5'-untranslated region but shared the rest of the sequence. Ribonuclease protection, RNA blotting, and primer extension revealed that MK2-type RNA was the major MK RNA in retinoic acid-treated embryonal carcinoma cells. In addition, the number of A residues in an oligo(A) stretch in the 5'-side of the common sequence differed from 9 to 29. The number was 9 in the most frequent cases, when the putative MK polypeptide had a molecular weight of about 15,500 and had a signal peptide-like sequence. Hybrid selected MK RNA yielded the predicted polypeptide upon in vitro translation. When pancreatic microsomal membranes were included in the translation system, the translation product of MK RNA was processed and entered into the lumen of the membranes. These results suggest that the product of the MK gene is an extracellular polypeptide.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2355021

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Nuclear targeting by the growth factor midkine.

Authors:  Yoshihisa Shibata; Takashi Muramatsu; Makoto Hirai; Tatsuya Inui; Terutoshi Kimura; Hidehiko Saito; Lynn M McCormick; Guojun Bu; Kenji Kadomatsu
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

2.  Midkine and pleiotrophin have bactericidal properties: preserved antibacterial activity in a family of heparin-binding growth factors during evolution.

Authors:  Sara L Svensson; Mukesh Pasupuleti; Björn Walse; Martin Malmsten; Matthias Mörgelin; Camilla Sjögren; Anders I Olin; Mattias Collin; Artur Schmidtchen; Ruth Palmer; Arne Egesten
Journal:  J Biol Chem       Date:  2010-03-22       Impact factor: 5.157

Review 3.  Structure and function of midkine as the basis of its pharmacological effects.

Authors:  T Muramatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 4.  Pancreatic cancer.

Authors:  C Güngör; B T Hofmann; G Wolters-Eisfeld; M Bockhorn
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

5.  Midkine promotes perineural invasion in human pancreatic cancer.

Authors:  Jun Yao; Wen-Yao Li; Shuo-Guo Li; Xiao-Shan Feng; She-Gan Gao
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

6.  Midkine, a heparin-binding protein, is increased in the diabetic mouse kidney postmenopause.

Authors:  Maggie K Diamond-Stanic; Melissa J Romero-Aleshire; Patricia B Hoyer; Kevin Greer; James B Hoying; Heddwen L Brooks
Journal:  Am J Physiol Renal Physiol       Date:  2010-11-03

7.  Recombinant human midkine stimulates proliferation of articular chondrocytes.

Authors:  Z H Zhang; H X Li; Y P Qi; L J Du; S Y Zhu; M Y Wu; H L Lu; Y Yu; W Han
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

Review 8.  Structural and functional changes linked to, and factors promoting, cytoplasmic maturation in mammalian oocytes.

Authors:  Masayasu Yamada; Yuuki Isaji
Journal:  Reprod Med Biol       Date:  2011-03-17

9.  Midkine is expressed and differentially processed during chronic obstructive pulmonary disease exacerbations and ventilator-associated pneumonia associated with Staphylococcus aureus infection.

Authors:  Helena M Linge; Cecilia Andersson; Sara L Nordin; Anders I Olin; Ann-Cathrine Petersson; Matthias Mörgelin; Amanda Welin; Johan Bylund; Leif Bjermer; Jonas Erjefält; Arne Egesten
Journal:  Mol Med       Date:  2013-09-30       Impact factor: 6.354

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.